002317 众生药业
已收盘 09-24 15:00:00
资讯
新帖
简况
9月24日众生药业跌6.30%，兴全趋势LOF基金重仓该股
证券之星 · 09-24 16:42
9月24日众生药业跌6.30%，兴全趋势LOF基金重仓该股
众生药业（002317）披露为合并报表范围内子公司提供担保的进展公告，9月22日股价上涨0.2%
证券之星 · 09-22
众生药业（002317）披露为合并报表范围内子公司提供担保的进展公告，9月22日股价上涨0.2%
研报掘金丨浙商证券：维持众生药业“买入”评级，创新转型进入兑现期
格隆汇 · 09-22
研报掘金丨浙商证券：维持众生药业“买入”评级，创新转型进入兑现期
9月21日众生药业涨5.12%，兴全趋势LOF基金重仓该股
证券之星 · 09-21
9月21日众生药业涨5.12%，兴全趋势LOF基金重仓该股
众生药业：来瑞特韦片（商品名
证券之星 · 09-10
众生药业：来瑞特韦片（商品名
众生药业（002317）披露将参加2026广东上市公司投资者集体接待日暨半年报业绩说明会活动，9月10日股价下跌3.16%
证券之星 · 09-10
众生药业（002317）披露将参加2026广东上市公司投资者集体接待日暨半年报业绩说明会活动，9月10日股价下跌3.16%
研报掘金丨东海证券：维持众生药业“买入”评级，创新研发快速推进
格隆汇 · 09-09
研报掘金丨东海证券：维持众生药业“买入”评级，创新研发快速推进
众生药业：推进ZSP1601片III期临床试验
证券之星 · 09-08
众生药业：推进ZSP1601片III期临床试验
众生药业(002317.SZ)：非诺贝特胶囊获批增加0.2g规格
智通财经 · 09-04
众生药业(002317.SZ)：非诺贝特胶囊获批增加0.2g规格
众生药业：为全资子公司众生医贸提供2亿元担保
格隆汇 · 09-04
众生药业：为全资子公司众生医贸提供2亿元担保
众生药业：乐睿灵已纳入2025年版国家医保目录
证券之星 · 09-03
众生药业：乐睿灵已纳入2025年版国家医保目录
众生药业：来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物
证券之星 · 09-03
众生药业：来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物
股市必读：众生药业新发布《关于控股子公司收到一类创新药昂拉地韦片新增适应症临床试验注册申请获得受理的公告》
证券之星 · 09-03
股市必读：众生药业新发布《关于控股子公司收到一类创新药昂拉地韦片新增适应症临床试验注册申请获得受理的公告》
众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理
智通财经 · 09-02
众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理
众生药业（002317）披露控股子公司获得来瑞特韦片晶型发明专利证书，8月27日股价上涨6.01%
证券之星 · 08-27
众生药业（002317）披露控股子公司获得来瑞特韦片晶型发明专利证书，8月27日股价上涨6.01%
8月27日众生药业涨6.01%，兴全趋势LOF基金重仓该股
证券之星 · 08-27
8月27日众生药业涨6.01%，兴全趋势LOF基金重仓该股
开源证券：给予众生药业买入评级
证券之星 · 08-27
开源证券：给予众生药业买入评级
众生药业（002317）2026年中报简析：净利润同比下降40.7%
证券之星 · 08-26
众生药业（002317）2026年中报简析：净利润同比下降40.7%
众生药业（002317）披露2026年半年度报告，8月24日股价下跌3.17%
证券之星 · 08-24
众生药业（002317）披露2026年半年度报告，8月24日股价下跌3.17%
众生药业（002317）披露收购控股子公司部分股权暨关联交易公告，8月17日股价上涨2.88%
证券之星 · 08-17
众生药业（002317）披露收购控股子公司部分股权暨关联交易公告，8月17日股价上涨2.88%
加载更多
公司概况
公司名称：
广东众生药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-12-11
主营业务：
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是中成药、化学药、原料药及中间体、中药材及中药饮片。
发行价格：
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":23.35,"timestamp":1790233398000,"preClose":24.92,"halted":0,"volume":22678885,"delay":0,"changeRate":-0.063,"floatShares":768000000,"shares":850000000,"eps":0.2345,"marketStatus":"已收盘","change":-1.57,"latestTime":"09-24 15:00:00","open":24.78,"high":24.9,"low":23.3,"amount":541000000,"amplitude":0.0642,"askPrice":23.35,"askSize":82,"bidPrice":23.34,"bidSize":145,"shortable":0,"etf":0,"ttmEps":0.2345,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":5,"adr":0,"adjPreClose":24.92,"symbolType":"stock","openAndCloseTimeList":[[1790213400000,1790220600000],[1790226000000,1790233200000]],"highLimit":27.41,"lowLimit":22.43,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":5.29,"roa":"--","peRate":99.573561,"roe":"2.73%","epsLYR":0.33,"committee":0.514456,"marketValue":19846000000,"turnoverRate":0.0295,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-28。","floatMarketCap":17933000000},"requestUrl":"/m/hq/s/002317","defaultTab":"news","newsList":[{"id":"2669632134","title":"9月24日众生药业跌6.30%，兴全趋势LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669632134","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669632134?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:42","pubTimestamp":1790239352,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日众生药业跌6.30%，收盘报23.35元，换手率2.95%，成交量22.68万手，成交额5.41亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共42家，其中持有数量最多的公募基金为兴证全球基金的兴全趋势LOF。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0188","163402","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669148867","title":"众生药业（002317）披露为合并报表范围内子公司提供担保的进展公告，9月22日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669148867","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669148867?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:31","pubTimestamp":1790069488,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，众生药业报收于25.51元，较前一交易日上涨0.2%，最新总市值为216.82亿元。该股当日开盘25.64元，最高26.5元，最低25.47元，成交额达7.99亿元，换手率为4.01%。众生药业于近日发布《关于公司为合并报表范围内子公司提供担保的进展公告》。本次担保后，公司对资产负债率低于70%的子公司累计担保余额为120,000万元，占公司最近一期经审计净资产的29.57%。公司无逾期担保、诉讼担保或因担保导致的败诉情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200030261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669311918","title":"研报掘金丨浙商证券：维持众生药业“买入”评级，创新转型进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669311918","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669311918?lang=zh_cn&edition=full","pubTime":"2026-09-22 14:43","pubTimestamp":1790059426,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","601878","BK0077","BK0239","BK0276","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669515924","title":"9月21日众生药业涨5.12%，兴全趋势LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669515924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669515924?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:44","pubTimestamp":1789980292,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日众生药业涨5.12%，收盘报25.46元，换手率3.7%，成交量28.39万手，成交额7.16亿元。重仓众生药业的前十大公募基金请见下表：该股最近90天内共有9家机构给出评级，买入评级7家，增持评级2家；过去90天内机构目标均价为32.65。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共42家，其中持有数量最多的公募基金为兴证全球基金的兴全趋势LOF。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["163402","BK0188","002317","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666595475","title":"众生药业：来瑞特韦片（商品名","url":"https://stock-news.laohu8.com/highlight/detail?id=2666595475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666595475?lang=zh_cn&edition=full","pubTime":"2026-09-10 20:52","pubTimestamp":1789044735,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业09月10日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，乐睿灵2025年上半年新冠流行带来较高销售基数，2026年上半年新冠低流行导致收入同比下滑。来瑞特韦片是公司自主研发的拥有全球自主知识产权的首个拟肽类3CL单药抗新冠病毒一类创新药，用于治疗轻中度新型冠状病毒感染的成年患者，销售与疾病流行态势相关。公司密切关注疾病动态情况，积极做好药品生产和销售工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000040060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561445","title":"众生药业（002317）披露将参加2026广东上市公司投资者集体接待日暨半年报业绩说明会活动，9月10日股价下跌3.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561445","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666561445?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:31","pubTimestamp":1789032709,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，众生药业报收于24.22元，较前一交易日下跌3.16%，最新总市值为205.85亿元。众生药业于近日披露《关于参加2026广东上市公司投资者集体接待日暨半年报业绩说明会活动的公告》。公告显示，公司将于2026年9月15日15:30-17:00通过‘全景路演’网站以网络远程方式参加由中国证券监督管理委员会广东监管局及广东上市公司协会主办、深圳市全景网络有限公司协办的‘2026广东上市公司投资者集体接待日暨半年报业绩说明会活动’。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666355588","title":"研报掘金丨东海证券：维持众生药业“买入”评级，创新研发快速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2666355588","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666355588?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:12","pubTimestamp":1788937933,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0077","BK0188","002317","161027","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373345","title":"众生药业：推进ZSP1601片III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373345","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665373345?lang=zh_cn&edition=full","pubTime":"2026-09-08 08:39","pubTimestamp":1788827951,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，ZSP1601片IIb期临床试验数据表现优异，展现出良好的疗效与安全性。三期临床试验计划于何时正式启动？公司积极推进与监管部门的沟通，并基于本次ZSP1601片IIb期临床试验结果，推进ZSP1601片III期临床试验。有关ZSP1601片的具体进展请以公司公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800005306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664399335","title":"众生药业(002317.SZ)：非诺贝特胶囊获批增加0.2g规格","url":"https://stock-news.laohu8.com/highlight/detail?id=2664399335","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664399335?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:58","pubTimestamp":1788515881,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的非诺贝特胶囊《药品补充申请批准通知书》，该药品增加0.2g规格的补充申请获得批准，视同通过仿制药质量和疗效一致性评价。据悉，非诺贝特有利尿酸、抗血小板凝集、使血浆中脂蛋白颗粒降解和甘油三酯清除的作用，可降低血清胆固醇20-25%，降低甘油三酯40-50%。非诺贝特胶囊临床用于治疗成人饮食控制疗法效果不理想的高胆固醇血症(IIa型)，内源性高甘油三酯血症，单纯型(IV型)和混合型(IIb和III型)。特别是饮食控制后血中胆固醇仍持续升高，或是有其他并发的危险因素时。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333201","title":"众生药业：为全资子公司众生医贸提供2亿元担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333201","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333201?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:46","pubTimestamp":1788515179,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664346872","title":"众生药业：乐睿灵已纳入2025年版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2664346872","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664346872?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:48","pubTimestamp":1788439702,"startTime":"0","endTime":"0","summary":"公司新冠创新药来瑞特韦片已纳入2025年版国家医保目录，公司打造高效的营销队伍，搭建五大核心标杆区域市场，以学术驱动、渠道协同、终端渗透为核心，全面加速创新药商业化进程。另外，公司乐睿灵已获得常规批准，目前正稳步推进乐睿灵向基层医疗机构、零售药店的拓展落地，逐步完善从等级医院到基层医疗机构、零售药店的全域渠道布局，全方位提升药品可及性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300039697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872366","title":"众生药业：来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872366","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664872366?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:48","pubTimestamp":1788439701,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业09月02日在投资者关系平台上答复投资者关心的问题。7-8月新冠流行回升，线上平台乐睿灵销量大幅增长，公司目前该产品实际出货情况如何？来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物，能够快速降低病毒滴度、缩短病毒转阴时间、显著缓解临床症状。公司将密切关注疾病动态情况，积极做好药品生产和销售工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300039696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","002317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843263","title":"股市必读：众生药业新发布《关于控股子公司收到一类创新药昂拉地韦片新增适应症临床试验注册申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843263","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664843263?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:17","pubTimestamp":1788369431,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司众生睿创于9月1日使用闲置自有资金7000万元购买结构性存款产品，期限56天，均为保本浮动收益型。产品均为保本浮动收益型，资金来源为闲置自有资金，投资期限内任一时点余额未超过董事会审批额度。公司已制定相关管理制度并采取多项风险控制措施，确保资金安全。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","06978","BK0188","BK0239","BK1574","159992","BK1161","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818429","title":"众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818429","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664818429?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:59","pubTimestamp":1788343190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，近日，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新药物昂拉地韦片新增适应症“治疗高并发症风险甲型流感”的药物临床试验申请获得国家药品监督管理局(NMPA)受理，并收到《受理通知书》。据悉，昂拉地韦片是具有明确作用机制和全球自主知识产权的全球首款流感RNA聚合酶PB2蛋白抑制剂，已于2025年5月获NMPA批准上市。此次昂拉地韦片新增适应症拟开展III期临床研究入组12岁及以上青少年和成人甲型流感参与者，评估昂拉地韦片治疗甲型流感病毒感染且存在流感相关并发症高风险参与者的有效性和安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","IBBQ","MDTX","BMED","BK0188","002317","IBBJ","PSYK","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662847708","title":"众生药业（002317）披露控股子公司获得来瑞特韦片晶型发明专利证书，8月27日股价上涨6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662847708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662847708?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:51","pubTimestamp":1787824271,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，众生药业报收于26.1元，较前一交易日上涨6.01%，最新总市值为221.83亿元。公司于近日披露《关于控股子公司获得发明专利证书的公告》。该专利为公司口服抗新型冠状病毒感染新药来瑞特韦片的晶型专利，属于项目核心专利。乐睿灵是公司自主研发的全球首个获得常规批准的3CL单药抗新冠病毒一类创新药，具有安全性更优、适用人群更广的特点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700042067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774092","title":"8月27日众生药业涨6.01%，兴全趋势LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774092","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662774092?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:49","pubTimestamp":1787820594,"startTime":"0","endTime":"0","summary":"证券之星消息，8月27日众生药业涨6.01%，收盘报26.1元，换手率3.77%，成交量28.96万手，成交额7.35亿元。重仓众生药业的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为兴证全球基金的兴全趋势LOF。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700039281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","002317","163402","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775976","title":"开源证券：给予众生药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662775976?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:40","pubTimestamp":1787812845,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,巢舒然近期对众生药业进行研究并发布了研究报告《公司信息更新报告：创新管线稳步推进，ZSP1601临床IIb期数据超预期》，给予众生药业买入评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750572","title":"众生药业（002317）2026年中报简析：净利润同比下降40.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750572?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:23","pubTimestamp":1787696600,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期众生药业发布2026年中报。根据财报显示，众生药业净利润同比下降40.7%。截至本报告期末，公司营业总收入10.0亿元，同比下降23.03%，归母净利润1.11亿元，同比下降40.7%。按单季度数据看，第二季度营业总收入3.76亿元，同比下降43.47%，第二季度归母净利润1160.1万元，同比下降88.98%。本文数据来源于众生药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661274904","title":"众生药业（002317）披露2026年半年度报告，8月24日股价下跌3.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661274904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661274904?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:03","pubTimestamp":1787580196,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，众生药业报收于25.34元，较前一交易日下跌3.17%，最新总市值为215.37亿元。该股当日开盘26.0元，最高26.39元，最低25.17元，成交额达6.44亿元，换手率为3.32%。近日，众生药业披露《2026年半年度报告》。报告显示，本报告期营业收入为1,000,420,115.22元，较上年同期下降23.03%；归属于上市公司股东的净利润为111,423,979.07元，同比下降40.70%；扣除非经常性损益后的净利润为120,783,851.89元，同比下降35.26%。经营活动产生的现金流量净额为541,753,332.27元，同比增长1,265.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400036671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433454","title":"众生药业（002317）披露收购控股子公司部分股权暨关联交易公告，8月17日股价上涨2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433454","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660433454?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:07","pubTimestamp":1786975657,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，众生药业报收于28.24元，较前一交易日上涨2.88%，最新总市值为240.02亿元。近日，众生药业披露《关于收购控股子公司部分股权暨关联交易的公告》。本次交易构成关联交易，已获董事会审议通过，无需提交股东大会审议，不构成重大资产重组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700034906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790485923167,"stockEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.084},{"period":"3month","weight":0.0336},{"period":"6month","weight":0.2712},{"period":"1year","weight":0.3278},{"period":"ytd","weight":0.2411}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":-0.0003},{"period":"3month","weight":-0.0345},{"period":"6month","weight":-0.0065},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"69037人(较上一季度减少37.81%)","perCapita":"11124股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是中成药、化学药、原料药及中间体、中药材及中药饮片。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}